Drug General Information
Drug ID
Former ID
Drug Name
Atinumab; Anti-Nogo-A mAbs, Novartis; Anti-Nogo-A monoclonal antibodies, Novartis; 11C7; 7B12
Drug Type
Indication Nerve injury [ICD-11: ND56.4; ICD-10: T14.4] Phase 1 [1]
Novartis AG
CAS Number
CAS 1226761-65-4
Target and Pathway
Target(s) Reticulon-4 (RTN4) Target Info . [2]
Pathway Interaction Database p75(NTR)-mediated signaling
Reactome Axonal growth inhibition (RHOA activation)
WikiPathways Spinal Cord Injury
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in leukocytes - TarBase
miR-targeted genes in epithelium - TarBase
Signalling by NGF
REF 1 ClinicalTrials.gov (NCT00406016) Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI. U.S. National Institutes of Health.
REF 2 Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012 June; 135(6): 1794-1818.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.